Literature DB >> 15967733

Effects of budesonide and N-acetylcysteine on acute lung hyperinflation, inflammation and injury in rats.

Anne-Helene Jansson1, Christina Eriksson, Xiangdong Wang.   

Abstract

Leukocyte activation and production of inflammatory mediators and reactive oxygen species are important in the pathogenesis of lipopolysaccharide (LPS)-induced acute lung injury. The present study investigated acute lung hyperinflation, edema, and lung inflammation 4 h after an intratracheal instillation of LPS (0.5, 2.5, 5, 10, 50, 100, 500, 1000, and 5000 microg/ml/kg). Effects of budesonide, an inhaled anti-inflammatory corticosteroids, and N-acetylcysteine (NAC), an antioxidant, were evaluated in Wistar rats receiving either low (2.5 microg/ml/kg) or high (50 microg/ml/kg) concentrations of LPS. This study demonstrates that LPS in a concentration-dependent pattern induces acute lung hyperinflation measured by excised lung gas volume (25-45% above control), lung injury indicated by increased lung weight (10-60%), and lung inflammation characterized by the infiltration of leukocytes (40-14000%) and neutrophils (80-17000%) and the production of cytokines (up to 2700%) and chemokines (up to 350%) in bronchoalveolar lavage fluid (BALF). Pretreatment with NAC partially prevented tumor necrosis factor alpha (TNFalpha) production induced by the low concentration of LPS, while pretreatment with budesonide totally prevented the increased production of TNFalpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low and high concentrations. Budesonide failed to prevent BALF levels of macrophage inflammatory protein (MIP)-2 and cytokine-induced neutrophil chemoattractant 1 (GRO/CINC-1) as well as lung hyperinflation induced by both low and high concentrations of LPS. Pretreatment with budesonide totally prevented the formation of lung edema at the low concentration of LPS and had partial effects on acute lung injury and leukocyte influx at the high concentrations. Thus, our data indicate that therapeutic effects of budesonide and NAC are dependent upon the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967733     DOI: 10.1016/j.vph.2005.03.006

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  16 in total

1.  Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.

Authors:  Sonali R Naikwade; Amrita N Bajaj; Prashant Gurav; Madhumanjiri M Gatne; Pritam Singh Soni
Journal:  AAPS PharmSciTech       Date:  2009-08-01       Impact factor: 3.246

Review 2.  Emerging therapies for the prevention of acute respiratory distress syndrome.

Authors:  Carl A Ruthman; Emir Festic
Journal:  Ther Adv Respir Dis       Date:  2015-05-22       Impact factor: 4.031

3.  Preventing ARDS: progress, promise, and pitfalls.

Authors:  Jeremy R Beitler; David A Schoenfeld; B Taylor Thompson
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

4.  Disruption of cytochrome P4501A2 in mice leads to increased susceptibility to hyperoxic lung injury.

Authors:  Lihua Wang; Krithika Lingappan; Weiwu Jiang; Xanthi I Couroucli; Stephen E Welty; Binoy Shivanna; Roberto Barrios; Gangduo Wang; M Firoze Khan; Frank J Gonzalez; L Jackson Roberts; Bhagavatula Moorthy
Journal:  Free Radic Biol Med       Date:  2015-02-10       Impact factor: 7.376

Review 5.  Inhalation therapies in acute respiratory distress syndrome.

Authors:  Antonio Artigas; Marta Camprubí-Rimblas; Neus Tantinyà; Josep Bringué; Raquel Guillamat-Prats; Michael A Matthay
Journal:  Ann Transl Med       Date:  2017-07

6.  Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome.

Authors:  Emir Festic; Gordon E Carr; Rodrigo Cartin-Ceba; Richard F Hinds; Valerie Banner-Goodspeed; Vikas Bansal; Adijat T Asuni; Daniel Talmor; Govindarajan Rajagopalan; Ryan D Frank; Ognjen Gajic; Michael A Matthay; Joseph E Levitt
Journal:  Crit Care Med       Date:  2017-05       Impact factor: 7.598

7.  Prehospital use of inhaled steroids and incidence of acute lung injury among patients at risk.

Authors:  Emir Festic; Enrique Ortiz-Diaz; Augustine Lee; Guangxi Li; Daryl J Kor; Adesanya Adebola; Ozan Akca; Jason Hoth; Joseph E Levitt; Rickey Carter; Ognjen Gajic
Journal:  J Crit Care       Date:  2013-09-24       Impact factor: 3.425

8.  Budesonide inhalation ameliorates endotoxin-induced lung injury in rabbits.

Authors:  Wei Gao; Nanying Ju
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-07

9.  Effect of glucocorticoid on MIP-1α and NF-κB expressing in the lung of rats undergoing mechanical ventilation with a high tidal volume.

Authors:  Zhi-Hong Liu; Xin-Ri Zhang; Xiao-Yun Hu; Meng-Yu Cheng; Jian-Ying Xu; Yong-Cheng Du
Journal:  World J Emerg Med       Date:  2011

Review 10.  Clinical review: Early treatment of acute lung injury--paradigm shift toward prevention and treatment prior to respiratory failure.

Authors:  Joseph E Levitt; Michael A Matthay
Journal:  Crit Care       Date:  2012-06-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.